Literature DB >> 1612753

Cholera toxin as a mucosal adjuvant: effects of H-2 major histocompatibility complex and lps genes.

C O Elson1.   

Abstract

In previous studies we found that cholera toxin (CT) can act as a mucosal adjuvant; i.e., it can stimulate an intestinal secretory immunoglobulin A (S-IgA) response to an unrelated protein antigen when both are fed together to mice. The purpose of this study was to determine whether the mucosal adjuvanticity of CT is restricted by either H-2 major histocompatibility complex or lps genes by using congenic inbred strains that differ at only a single genetic locus. Groups of five mice each were fed saline, CT (10 micrograms), keyhole limpet hemocyanin (KLH) (5 mg), or both CT and KLH on four different days, and samples of intestinal secretions and plasma were obtained 1 week after the last feeding. In the mice fed both CT and KLH, the intestinal S-IgA anti-KLH response was higher in H-2b congenic strains than in H-2k congenic strains, and in addition there was a highly significant positive correlation between the intestinal S-IgA anti-KLH and S-IgA anti-CT responses in the intestinal secretions of individual mice. Similarly, in the lps congenic strains, mice of the endotoxin-responsive strain that were fed both CT and KLH had substantially higher S-IgA and plasma IgG responses to KLH than did mice of the endotoxin-unresponsive strain. The effect of CT on the induction of oral tolerance to KLH in the H-2 congenic strains was also examined. In contrast to the results above, the abrogation of oral tolerance to KLH by CT occurred in all strains regardless of H-2 haplotype. Similarly, the adjuvant effect of CT on plasma IgG anti-KLH responses after both were given together intraperitoneally was not restricted by H-2. I conclude that the mucosal adjuvanticity of CT is influenced by both the H-2 and lps genetic loci and that it appears to depend on a vigorous mucosal immune response to CT itself.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1612753      PMCID: PMC257248          DOI: 10.1128/iai.60.7.2874-2879.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Gangliosides and membrane receptors for cholera toxin.

Authors:  P Cuatrecasas
Journal:  Biochemistry       Date:  1973-08-28       Impact factor: 3.162

2.  Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin.

Authors:  C O Elson; W Ealding
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

3.  Development of improved cholera vaccine based on subunit toxoid.

Authors:  J Holmgren; A M Svennerholm; I Lönnroth; M Fall-Persson; B Markman; H Lundbeck
Journal:  Nature       Date:  1977-10-13       Impact factor: 49.962

4.  The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens.

Authors:  N Lycke; U Karlsson; A Sjölander; K E Magnusson
Journal:  Scand J Immunol       Date:  1991-06       Impact factor: 3.487

5.  Expression of GM1 and GD1a in liver of wild mice.

Authors:  Y Hashimoto; A Suzuki; T Yamakawa; C H Wang; F Bonhomme; N Miyashita; K Moriwaki
Journal:  J Biochem       Date:  1984-01       Impact factor: 3.387

6.  Simultaneous induction of antigen-specific IgA helper T cells and IgG suppressor T cells in the murine Peyer's patch after protein feeding.

Authors:  L K Richman; A S Graeff; R Yarchoan; W Strober
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

7.  A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions.

Authors:  C O Elson; W Ealding; J Lefkowitz
Journal:  J Immunol Methods       Date:  1984-02-24       Impact factor: 2.303

8.  Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit intestine.

Authors:  N F Pierce; J B Kaper; J J Mekalanos; W C Cray; K Richardson
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

9.  The role of antigen form and function in the primary and secondary intestinal immune responses to cholera toxin and toxoid in rats.

Authors:  N F Pierce
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

10.  Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide.

Authors:  A G JOHNSON; S GAINES; M LANDY
Journal:  J Exp Med       Date:  1956-02-01       Impact factor: 14.307

View more
  6 in total

1.  Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.

Authors:  H Y Wu; M W Russell
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

2.  Deficient induction of the immune response to oral immunization with cholera toxin in malnourished rats during suckling.

Authors:  J Fló; M E Roux; E Massouh
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

3.  A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.

Authors:  William M Gwinn; Brandi T Johnson; Shaun M Kirwan; Ashley E Sobel; Soman N Abraham; Michael D Gunn; Herman F Staats
Journal:  Vaccine       Date:  2013-01-23       Impact factor: 3.641

4.  Alga-produced cholera toxin-Pfs25 fusion proteins as oral vaccines.

Authors:  James A Gregory; Aaron B Topol; David Z Doerner; Stephen Mayfield
Journal:  Appl Environ Microbiol       Date:  2013-04-19       Impact factor: 4.792

5.  Oral immunization with Toxoplasma gondii antigens in association with cholera toxin induces enhanced protective and cell-mediated immunity in C57BL/6 mice.

Authors:  I Bourguin; T Chardès; D Bout
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

6.  The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice.

Authors:  R L Ferrero; J M Thiberge; I Kansau; N Wuscher; M Huerre; A Labigne
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.